For patients with BRAF V600E mutant CRC, combination therapy with PD-1, BRAF, and MEK inhibitors significantly increased the clinical objective response rate (cORR) to 25% (95% CI 10.7%–44.9%). Here, MAP2K7 is linked to colorectal carcinoma.